Users online: 3071    [ij] [ij] [ij] 
Email id

Research Journal of Engineering and Technology
Year : 2019, Volume : 10, Issue : 1
First page : ( 11) Last page : ( 15)
Print ISSN : 0976-2973. Online ISSN : 2321-581X.
Article DOI : 10.5958/2321-581X.2019.00003.5

Kinetic Study of Granzyme B in Patients with Chronic Hepatitis Type B

Alshamary Hussein S.1, AL-Timimi Raid J. M.1, Ali Jalal A.2, Al-Mayah Qasim S.3

1Department of Chemistry and Biochemistry, College of Medicine, Al-Nahrain University, Iraq

2Consultant Gastro and Hepatology, College of Medicine, Al-Nahrain University, Iraq

3Medical Research Unit, College of Medicine, Al-Nahrain University, Iraq

Corresponding Author E-mail: sciencefond2015@gmail.com

Online published on 18 May, 2019.


Chronic hepatitis B (CHB) virus infection is affecting more than 350 million people worldwide, and can predispose for serious complications like liver cirrhosis and hepatocarcinoma. The development of CHB from active stage is the direct result of debilitated immune system which mainly depends on cytotoxic T-lymphocyte (CTL) and natural killer (NK) cells for controlling viral replication. These cells eliminate their targets through the secretion of two proteins: perforin and granzymes (Gzms). Thus, this study aimed to evaluate the activity and concentration of GzmB in patients with CHB. A total of 60 patients (30 newly diagnosed and 30 treated) were recruited for this case-control study. Other 30 age-and gender-matched apparently healthy subjected (negative for HBsAg) were involved as controls. Granzyme B kinetics and concentration were measured using ready commercial kits. Treated patients had significantly higher values of Km (8.57±0.796 X 10¯5 M), than either untreated patients (7.17±0.69 X 10¯5 M) or controls (7.24±0.82 X 10¯5 M), while treated patients showed significantly lower values for Kcat and Kcat/Km (3.77±0.39 s¯1 and 4.55±0.89 x 104 M¯1. s¯1 respectively) than either untreated patients (4.37±0.31 s¯1 and 6.18±0.98 x 104 M¯1. s¯1 respectively) or controls (4.34±0.37 s¯1 and 6.187±1.167 x 104 M¯1. s¯1 respectively). Mean GzmB concentration in control was 104.4±26.37 Pg/mL which significantly higher than that of untreated patients (44.3±8.73 Pg/mL which did not differ significantly from treated patients (42.33±9.09 Pg/mL). These data indicate the reduction in GzmB concentration in CHB which may reflect a defect in the production of this enzyme that predispose un individual to the chronic infection.



Granzyme B, Hepatitis B, Kinetics.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
575,015,596 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.